Effect of Nicorandil Combined with Rosuvastatin on Cardiac Function and Oxidative Stress in Patients with Unstable Angina Pectoris
Objective:To explore the clinical efficacy of nicorandil combined with rosuvastatin in the treatment of patients with unstable angina pectoris(UAP)and its effect on cardiac function and oxidative stress.Methods:A total of 120 UAP patients treated in a hospital from June 2022 to June in 2023 were selected and assigned to the control group(3 cases shedding,n=57)and observation group(n=60)by random number table method.Patients in both groups were given conventional treatment including antihypertensive,antiplatelet and improved myocardial metabolism.The control group was additionally treated with nitroglycerin injection,and the observation group was additionally given nicorandil tablets combined with rosuvastatin calcium tablets.Both groups were treated for 3 months.The cardiac function indicators[left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD)],myocardial injury index[creatine kinase isoenzyme(CK-MB),cardiac troponin I(cTnI)and oxidized low density lipoprotein(ox-LDL)],oxidative stress markers[superoxide dismutase(SOD),reduce glutathione(GSH)],inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)],frequency and duration of angina pectoris attacks,clinical response and adverse reactions were compared between the two groups.Results:After treatment,The LVEDD and LVESD were decreased in both groups(P<0.05),and were lower in the observation group as compared with the control group(P<0.05).The LVEF was increased in both groups(P<0.05),and was higher in the observation group as compared with the control group(P<0.05).The levels of CK-MB,cTnI and ox-LDL were decreased in both groups(P<0.05),and were lower in the observation group as compared with the control group(P<0.05).The levels of SOD and GSH were increased in both groups(P<0.05),and were higher in the observation group as compared with the control group(P<0.05).The levels of hs-CRP and IL-6 were decreased in both groups(P<0.05),and were lower in the observation group as compared with the control group(P<0.05).The frequency and duration of angina pectoris attacks were decreased in both groups(P<0.05),and were lower in the observation group as compared with the control group(P<0.05).The total response rate in the observation group(88.33%)was higher than that in the control group(71.93%,P<0.05).No statistically significant difference in the total incidence of adverse reactions was observed between the two groups(P>0.05).Conclusion:In addition to the conventional treatment,nicorandil combined with rosuvastatin demonstrated definite clinical efficacy in the treatment of UAP patients,with effectively improved cardiac function,mitigated inflammation and oxidative stress,without additional risk of adverse reactions.
万方数据
维普
